Advertisement
Screener

ALDEYRA THERAPEUTICS, INC. (ALDX) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Aldeyra Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Aldeyra Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -60.85%, a change of 30.71% year-over-year.
  • Aldeyra Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -64.92%, a change of 25.80% year-over-year.
  • Aldeyra Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -76.49%, a change of 2.17% year-over-year.
  • Aldeyra Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -87.71%, a change of -35.07% year-over-year.
  • Aldeyra Therapeutics, Inc. return tang equity for fiscal 2025 was -76.49%, a change of 2.17% from fiscal 2024.
  • Aldeyra Therapeutics, Inc. return tang equity for fiscal 2024 was -78.66%, a change of -47.32% from fiscal 2023.
  • Aldeyra Therapeutics, Inc. return tang equity for fiscal 2023 was -31.34%, a change of 9.73% from fiscal 2022.
  • Aldeyra Therapeutics, Inc. return tang equity for fiscal 2022 was -41.07%, a change of -12.99% from fiscal 2021.
Available history
2013-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-60.85%-$23.05M$37.89M
2026-03-31-64.92%-$27.37M$42.16M
2025-12-31-76.49%-$33.85M$44.25M
2025-09-30-87.71%-$43.19M$49.24M
2025-06-30-91.55%-$50.62M$55.29M
2025-03-31-90.72%-$57.7M$63.6M
2024-12-31-78.66%-$55.85M$71M
2024-09-30-52.64%-$44.8M$85.1M
2024-06-30-38.52%-$37.87M$98.31M
2024-03-31-26.46%-$30.01M$113.42M
2023-12-31-31.34%-$37.54M$119.8M
2023-09-30-37.15%-$45.69M$123.01M
2023-06-30-40.08%-$52.06M$129.88M
2023-03-31-44.34%-$60.85M$137.24M
2022-12-31-41.07%-$62.02M$151.01M
2022-09-30-40.00%-$64.88M$162.19M
2022-06-30-37.99%-$66.12M$174.03M
2022-03-31-33.18%-$63.27M$190.69M
2021-12-31-28.08%-$57.78M$205.74M
2021-09-30-24.27%-$53.31M$219.67M
2021-06-30-19.85%-$46.39M$233.68M
2021-03-31-30.91%-$38.98M$126.07M
2020-12-31-63.11%-$37.55M$59.51M
2020-09-30-56.99%-$39.42M$69.17M
2020-06-30-93.32%-$49.26M$52.79M
2020-03-31-126.68%-$55.07M$43.47M
2019-12-31-126.51%-$60.83M$48.08M
2019-09-30-114.58%-$58.3M$50.88M
2019-06-30-74.85%-$50.4M$67.33M
2019-03-31-58.77%-$46.12M$78.48M
2018-12-31-44.90%-$38.89M$86.62M
2018-09-30-123.15%-$35.21M$28.6M
2018-06-30-79.47%-$29.39M$36.98M
2018-03-31-71.24%-$25.65M$36M
2017-12-31-56.41%-$22.34M$39.6M
2017-09-30-43.65%-$20.04M$45.9M
2017-06-30-84.95%-$19.83M$23.34M
2017-03-31-67.23%-$18.82M$28M
2016-12-31-86.36%-$18.7M$21.65M
2016-09-30-71.68%-$18.4M$25.67M
2016-06-30-57.56%-$16.99M$29.52M
2016-03-31-72.69%-$14.92M$20.53M
2015-12-31-48.60%-$12.09M$24.88M
2015-09-30-35.47%-$10.18M$28.7M
2015-06-30-27.99%-$8.82M$31.52M
2015-03-31-55.87%-$7.73M$13.83M
2014-12-31-82.55%-$5.19M$6.28M
2014-09-3079.30%$6.55M$8.26M
2014-06-30182.08%$17.87M$9.81M
2014-03-31-43.98%$17.44M-$39.65M
2013-12-31-32.47%$13.06M-$40.22M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-76.49%-$33.85M$44.25M
2024-12-31-78.66%-$55.85M$71M
2023-12-31-31.34%-$37.54M$119.8M
2022-12-31-41.07%-$62.02M$151.01M
2021-12-31-28.08%-$57.78M$205.74M
2020-12-31-63.11%-$37.55M$59.51M
2019-12-31-126.51%-$60.83M$48.08M
2018-12-31-44.90%-$38.89M$86.62M
2017-12-31-56.41%-$22.34M$39.6M
2016-12-31-86.37%-$18.7M$21.65M
2015-12-31-48.60%-$12.09M$24.88M
2014-12-31-82.55%-$5.19M$6.28M
2013-12-31-32.47%$13.06M-$40.22M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
iBio, Inc. (IBIO)United States$0.077B-2.94
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30